About Adaptive Match
What is Adaptive Match?
Adaptive Match is a data processing tool designed to match inputted CDR3s to inputted, candidate antigen, amino acid sequences. The match is based on chemical complementarity, and potentially on other user data, such as survival and gene expression distinctions associated with the complementarity.
Previous Work with Adaptive Match
Initially, Adaptive Match was used to analyze data regarding cancer patients. This work has resulted in the following publications:
- Yeagley M, Chobrutskiy BI, Gozlan EC, Medikonda N, Patel DN, Falasiri S, Callahan BM, Huda T, Blanck G. Electrostatic Complementarity of T-Cell Receptor-Alpha CDR3 Domains and Mutant Amino Acids Is Associated with Better Survival Rates for Sarcomas. Pediatr Hematol Oncol. 2021 Feb 22:1-14. doi: 10.1080/08880018.2020.1843576. Epub ahead of print. PMID: 33616477.
- Chobrutskiy BI, Yeagley M, Diviney A, Zaman S, Gozlan EC, Tipping P, Koohestani DM, Roca AM, Blanck G. A scoring system for the electrostatic complementarities of T-cell receptors and cancer-mutant amino acids: multi-cancer analyses of associated survival rates. Immunology. 2020 Apr;159(4):373-383. doi: 10.1111/imm.13165. Epub 2020 Jan 21. PMID: 31821535.
- Chobrutskiy BI, Yeagley M, Tipping P, Zaman S, Diviney A, Patel DN, Falasiri S, Uversky VN, Blanck G. Chemical complementarity between immune receptor CDR3s and IDH1 mutants correlates with increased survival for lower grade glioma. Oncogene. 2020 Feb;39(8):1773-1783. doi: 10.1038/s41388-019-1101-2. Epub 2019 Nov 18. PMID: 31740784.
- Arturo JF, Chobrutskiy BI, Yeagley M, Patel DN, Falasiri S, Patel JS, Blanck G. Electrostatic complementarity of B-cell receptor CDR3s and TP53-mutant amino acids in breast cancer is associated with increased disease-free survival rates. Cell Mol Immunol. 2020 Jul;17(7):776-778. doi: 10.1038/s41423-019-0328-8. Epub 2019 Nov 15. PMID: 31729463.
Screen size not supported.
Please switch to desktop browser.